iView Therapeutics

Cranbury, NJ · Founded 2015 · Privately Held (backing)

Developer of topical drugs designed for applications in ophthalmology, dermatology, and otolaryngology. iView Therapeutics is based in Cranbury, NJ and was founded in 2015. It was valued at $107 million at its later-stage round in Jun 2025, the last priced event on record. It has raised $39.2 million across 2 recorded rounds; the latest was a $9.2 million early-stage round in May 2024.

PMV mark · valuation
$107.4M
Oct 2026
Priced at
its later-stage round
Jun 2025
Total raised
$39.2M
Last round
Early Stage VC
May 2024
What is iView Therapeutics worth?
$107.4MPrivateMarketView mark · Oct 2026

Valued at $107.4M at its later-stage round, Jun 2025. Nothing has traded since.

Free account
More of iView Therapeutics with a free account
  • ·The complete investor list: 16 names
  • ·Watch iView Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

iView Therapeutics funding history

2 rounds
DateRoundRaisedPost-money
May 2024Early Stage VC$9.2M▮
Feb 2021Early Stage VC$30.0M▮
Unlock post-money valuations

Membership and data by Private Market View

iView Therapeutics valuation

iView Therapeutics was valued at $107 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has iView Therapeutics raised?

iView Therapeutics has raised $39.2 million across 2 recorded rounds since 2021. The largest was a $9.2 million early-stage round in May 2024.

iView Therapeutics has filed 4 Form Ds with the SEC since 2022, most recently in Jun 2025 ($9.2 million sold to 5 investors).

How iView Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For iView Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about iView Therapeutics

What is iView Therapeutics worth?
iView Therapeutics is valued at $107.4M as of Oct 2026. Valued at $107.4M at its later-stage round, Jun 2025. Nothing has traded since.
How much has iView Therapeutics raised?
iView Therapeutics has raised $39.2M in total funding across 2 recorded rounds.
When did iView Therapeutics last raise?
iView Therapeutics last raised in May 2024 (Early Stage VC), raising $9.2M.